REVIEW PAPER
The roles of vaspin, chemerin, and omentin in the determination of metabolic syndrome
Submission date: 2018-04-19
Final revision date: 2018-06-14
Acceptance date: 2018-06-15
Publication date: 2018-06-30
Medical Studies 2018;34(2):160-177
KEYWORDS
TOPICS
ABSTRACT
Metabolic syndrome (MetS) is defined as multiple risk factors including abdominal obesity, dyslipidaemia, abnormal glycaemia, and elevated blood pressure. The incidence of MetS and pathophysiological mechanisms underlying its development are still not fully understood. It is thought that the occurrence of MetS arises from the complex relationship between genetic and environmental factors. The aim of the study was to overview and summarise current knowledge regarding genetic determinants of MetS. Also analysed were the relationship between polymorphisms of the genes encoding selected adipokines (vaspin, chemerin, omentin) and the risk of MetS, as well as other metabolic disorders. The precise determination of MetS genotype is difficult because metabolic syndrome occurrence is a combination of multiple risk factors. A thorough understanding of pathomechanisms of MetS, involving selected adipokines, may in the future allow the use of these adipokines as potential biomarkers of metabolic disorder risk.
REFERENCES (194)
1.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
2.
Lakka HM. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
3.
Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007; 28: 857-864.
4.
Aggarwal A, Aggarwal S, Sharma V. Cardiovascular risk factors in young patients of coronary artery disease: differences over a decade. J Cardiovasc Thorac Res 2014; 6: 169-173.
5.
Abbasalizad M, Jahangiry L, Asghari-jafarabadi M, Najafi M. Association between dietary patterns and metabolic syndrome in a sample of Tehranian adults. Obesity Res Clin Pract 2016; 10 (Suppl 1): S64-73.
6.
Majda A, Zalewska-Puchała J, Kamińska A, Bodys-Cupak I, Suder M. Risk factors for diseases of the cardiovascular system among Catholics living in areas of southern Poland. Medical Studies 2017; 33: 88-94.
7.
Sadowski M, Janion-Sadowska A. The management of patients with cardiogenic shock. Medical Studies 2017; 33: 55-62.
8.
Gathirua-Mwangi WG, Monahan PO, Murage MJ, Zhang J. Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey. Cancer Causes Control 2017; 28: 127-136.
9.
Kozłowska-Geller M. Mechanisms of carcinogenesis in colorectal cancer. Medical Studies 2017; 33: 308-315.
10.
Khan RJ, Gebreab SY, Sims M, Riestra P, Xu R, Davis SK. Prevalence, associated factors and heritabilities of metabolic syndrome and its individual components in African Americans: the Jackson Heart Study. BMJ Open 2015; 5: e008675.
11.
Zarkesh M, Asghari G, Amiri P, Hosseinzadeh N, Hedayati M, Ghanbarian A. Familial aggregation of metabolic syndrome with different socio-behavioral characteristics: the fourth phase of Tehran Lipid and Glucose Study. Iran Red Crescent Med J 2016; 18: e30104.
12.
Lin HF, Boden-Albala B, Juo SH, Park N, Rundek T, Sacco RL. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia 2005; 48: 2006-2012.
13.
Bellia A, Giardina E, Lauro D, Tesauro M, Fede G Di, Cusumano G, Federici M, Rini GB, Novelli G, Laurao R, Sbraccia P. “The Linosa Study’”: epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutrition Metabolism Cardiovasc Dis 2009; 19: 455-461.
14.
Panizzon MS, Hauger RL, Sailors M, Lyons MJ, Jacobson KC, Murray RE, Rana B, Vasilopoulos T, Vuoksimaa E, Xian H, Kremen WS, Franz CE. A new look at the genetic and environmental coherence of metabolic syndrome components. Obesity 2015; 23: 2499-2507.
15.
Cameron A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas 2010; 65: 117-121.
16.
Zabaneh D, Balding DJ. A genome-wide association study of the metabolic syndrome in Indian Asian men. PLoS One 2010; 5: e11961.
17.
Xi B, Ruiter R, Chen J, Pan H, Wang Y, Mi J. The ACE insertion/deletion polymorphism and its association with metabolic syndrome. Metabolism 2012; 61: 891-897.
18.
Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, Havulinna AS, Stancáková A, Barnes C, Widen E, Kajantie E, Eriksson JG, Viikari J, Kähönen M, Lehtimäki T, Raitakari OT, Hartikainen AL, Ruokonen A, Pouta A, Jula A, Kangas AJ, Soininen P, Ala-Korpela M, Männistö S, Jousilahti P, Bonnycastle LL, Järvelin MR, Kuusisto J, Collins FS, Laakso M, Hurles ME, Palotie A, Peltonen L, Ripatti S, Salomaa V. Genome-wide screen for metabolic syndrome susceptibility loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circulation Cardiovasc Genet 2012; 5: 242-249.
19.
Povel CM, Boer JMA, Reiling E, Feskens EJM. Genetic variants and the metabolic syndrome: a systematic review. Obes Rev 2011; 12: 952-967.
20.
Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, Kullo IJ, Sovio U, Mathias RA, Sun YV, Franceschini N, Absher D, Li G, Zhang Q, Feitosa MF, Glazer NL, Haritunians T, Hartikainen AL, Knowles JW, North KE, Iribarren C, Kral B, Yanek L, O’Reilly PF, McCarthy MI, Jaquish C, Couper DJ, Chakravarti A, Psaty BM, Becker LC, Province MA, Boerwinkle E, Quertermous T, Palotie L, Jarvelin MR, Becker DM, Kardia SL, Rotter JI, Chen YD, Borecki IB. A bivariate genome-wide approach to metabolic syndrome: STAMPEED Consortium. Diabetes 2011; 60: 1329-1339.
21.
Lin E, Kuo P, Liu Y, Yang AC, Tsai S. Detection of susceptibility loci on APOA5 and COLEC12 associated with metabolic syndrome using a genome-wide association study in a Taiwanese population. Oncotarget 2017; 8: 93349-93359.
22.
Avery CL, He Q, North KE, Ambite JL, Boerwinkle E, Fornage M. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet 2011; 7: e1002322.
23.
Carty CL, Bhattacharjee S, Haessler J, Al E. Comparative analysis of metabolic syndrome components in over 15,000 African Americans identifies pleiotropic variants: results from the PAGE Study. Circ Cardiovasc Genet 2014; 7: 505-513.
24.
Jeong SW, Chung M, Park S, Cho SB, Hong K. Genome-wide association study of metabolic syndrome in Koreans. Genom Informatics 2014; 12: 187-194.
25.
Tekola-Ayele F, Doumatey AP, Shriner D, Bentley AR, Chen G, Zhou J, Fasanmade O, Johnson T, Oli J, Okafor G,Eghan BA Jr, Agyenim-Boateng K, Adebamowo C, Amoah A, Acheampong J, Adeyemo A, Rotimi CN. Genome-wide association study identifies African-ancestry specific variants for metabolic syndrome. Mol Genet Metab 2015; 116: 305-313.
26.
Zhang L, Dai Y, Bian L, Wang W, Wang W, Muramatsu M, Hua Q. Association of the cell death-inducing DNA fragmentation factor alpha-like effector A (CIDEA) gene V115F (G/T) polymorphism with phenotypes of metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 2011; 91: 233-238.
27.
Ghattas MH, Mehanna ET, Mesbah NM, Abo-elmatty DM. Association of estrogen receptor alpha gene polymorphisms with metabolic syndrome in Egyptian women. Metabolism 2013; 62: 1437-1442.
28.
Povel CM, Boer JM, Onland-Moret N, Dollé ME, Feskens EJ, van der Schouw YT. Single nucleotide polymorphisms (SNPs) involved in insulin resistance, weight regulation, lipid metabolism and inflammation in relation to metabolic syndrome: an epidemiological study. Cardiovasc Diabetol 2012; 11: 133.
29.
Kordi-Tamandani DM, Hashemi M, Sharifi N, Kaykhaei MA, Torkamanzehi A. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. Mol Biol Rep 2012; 39: 937-943.
30.
Gupta V, Gupta A, Jafar T, Gupta V, Agrawal S, Srivastava N, Kumar S, Singh AK, Natu SM, Agarwal CG, Agarwal GG. Association of TNF-promoter gene G-308A polymorphism with metabolic syndrome, insulin resistance, serum TNF- and leptin levels in Indian adult women. Cytokine 2012; 57: 32-36.
31.
Hashemi M, Rezaei H, Kaykhaei M, Taheri M. A 45-bp insertion/deletion polymorphism of UCP2 gene is associated with metabolic syndrome. J Diab Metab Disord 2014; 13: 12.
32.
Zhang L, You Y, Wu Y, Zhang Y, Wang M, Song Y, Liu X, Kou C. Association of BUD13 polymorphisms with metabolic syndrome in Chinese population: a case-control study. Lipids Health Disease 2017; 16: 127.
33.
Mirhafez SR, Avan A, Pasdar A, Khatamianfar S, Hosseinzadeh L, Ganjali S, Movahedi A, Pirhoushiaran M, Gómez Mellado V, Rosace D, van Krieken A, Nohtani M, Ferns GA, Ghayour-Mobarhan M. Zinc finger 259 gene polymorphism rs964184 is associated with serum triglyceride levels and metabolic syndrome. Int J Mol Cell Med 2016; 5: 8-18.
34.
Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci 2005; 102: 10610-10615.
35.
Heiker JT, Klöting N, Kovacs P, Kuettner EB, Sträter N, Schultz S, Kern M, Stumvoll M, Blüher M, Beck-Sickinger AG. Vaspin inhibits kallikrein 7 by serpin mechanism. Cell Mol Life Sci 2013; 70: 2569-2583.
36.
Schleinitz D. Genetic determination of serum levels of diabetes-associated adipokines. Rev Diab Stud 2015; 12: 277-298.
37.
Dimova R, Tankova T. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. BioMed Res Int 2015; 2015: 823481.
38.
Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Blüher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-377.
39.
Hida K, Poulsen P, Teshigawara S, Nilsson E, Friedrichsen M, Ribel-Madsen R, Grunnet L, Lund SS, Wada J, Vaag A. Impact of circulating vaspin levels on metabolic variables in elderly twins. Diabetologia 2012; 55: 530-532.
40.
Kim JM, Kim TN, Won JC. Association between serum vaspin level and metabolic syndrome in healthy Korean subjects. Metab Syndr Relat Disord 2013; 11: 385-391.
41.
Chang HM, Patk HS, Song YS, Jang YJJ. Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects. Metab Clin Exp 2010; 59: 1276-1281.
42.
Körner A, Neef M, Friebe D, Erbs S, Kratzsch J, Dittrich K, Blüher S, Kapellen TM, Kovacs P, Stumvoll M, Blüher M, Kiess W. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int J Obes 2011; 35: 578-586.
43.
Xu X, Wen J, Lu Y, Ji H, Zhuang J, Su Y, Liu B, Li H, Xu Y. Impact of age on plasma vaspin concentration in a group of normal Chinese people. J Endocrinol Investig 2017; 40: 143-151.
44.
Wyskida K, Franik G, Wikarek T, Owczarek A, Delroba A, Chudek J, Sikora J, Olszanecka-Glinianowicz M. The levels of adipokines in relation to hormonal changes during the menstrual cycle in young, normal-weight women. Endocr Connect 2017; 6: 892-900.
45.
Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008; 57: 1501-1507.
46.
Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diab Res Clin Pract 2009; 84: 325-328.
47.
Bluher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 2012; 41: 176-182.
48.
Feng R, Li Y, Wang C, Luo C, Liu L. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diab Res Clin Pract 2014; 106: 88-94.
49.
Saboori S, Hosseinzadeh-attar MJ, Yousefi E, Hosseini M. The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. Diabetes Metab Syndr Clin Res Rev 2015; 9: 320-323.
50.
Yang W, Li Y, Tian T, Wang L. Serum vaspin concentration in elderly type 2 diabetes mellitus patients with differing body mass index: a cross-sectional study. BioMed Res Int 2017; 2017: 4875026.
51.
Liu P, Li G, Wu J, Zhou X, Wang L, Han W, Lv Y, Sun C. Vaspin promotes 3T3-L1 preadipocyte differentiation. Exp Biol Med 2015; 240: 1520-1527.
52.
Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocr 2011; 75: 628-635.
53.
Faramarzi M, Banitalebi E, Nori S, Farzin S, Taghavian Z. Effects of rhythmic aerobic exercise plus core stability training on serum omentin, chemerin and vaspin levels and insulin resistance of overweight women. J Sports Med Phys Fitness 2016; 56: 476-482.
54.
Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, Broch M, Aguilar C, Olona M, Porras JA, Hernandez M, Sabench F, del Castillo D, Richart C. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011; 12: 60.
55.
Sperling M, Grzelak T, Pelczyńska M, Jasinska P, Bogdanski P, Pupek-Musialik D, Czyzewska K. Concentrations of omentin and vaspin versus insulin resistance in obese individuals. Biomed Pharmacother 2016; 83: 542-547.
56.
Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Exp Opinon Investig Drugs 2008; 17: 327-333.
57.
Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Vaspin gene expression in human adipose tissue: Association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436.
58.
Yang W, Li Y, Tian T, Wang L, Lee P, Hua Q. Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications. BMC Endocr Disord 2017; 17: 67.
59.
Atya H, Hassan Z, Amin A, Al E. Vaspin concentration in obesity, impaired glucose tolerance and type 2 diabetes in Egypt. Adv Res Biol Sci 2013; 1: 6-13.
60.
Dimova R, Tankova T, Kirilov G, Chakarova N, Dakov-ska L, Grozeva G. Is vaspin related to cardio‑metabolic status and autonomic function in early stages of glucose intolerance and in metabolic syndrome? Diabetol Metab Syndr 2016; 8: 46.
61.
Li K, Li L, Yang M, Liu H, Liu D, Yang H, Boden G, Yang G. Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity. Eur J Endocrinol 2011; 164: 905-910.
62.
Ye Y, Hou X, Pan X, Lu J, Jia W. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J 2009; 122: 2530-2533.
63.
Bilir BE, Guldiken S, Tuncbilek N, Demir AM, Polat A. The effects of fat distribution and some adipokines on insulin resistance in subjects with prediabetes. Endokrynol Pol 2016; 67: 277-282.
64.
Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009; 160: 65-70.
65.
Jian W, Peng W, Xiao S, Li H, Jin J, Qin L, Dong Y, Su Q. Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study. PLoS One 2014; 9: e94763.
66.
Kempf K, Rose B, Illig T, Rathmann W, Strassburger K, Thorand B, Meisinger C, Wichmann HE, Herder C, Vollmet C. Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies. Exp Clin Endocrinol Diab 2010; 118: 184-189.
67.
Yan T, Li L, Wang H, Wang J, Cai D. Correlation between adipocytokines levels and metabolic syndrome in type 2 diabetes mellitus. J South Med Univ 2014; 34: 275-278.
68.
Abdel Ghany SM, Sayed AA, El-deek SEM, Elbadre HM, Dahpy MA, Saleh MA, Sharaf El-Deen H, Mustafa MH. Obesity risk prediction among women of Upper Egypt: the impact of serum vaspin and vaspin rs2236242 gene polymorphism. Gene 2017; 626: 140-148.
69.
Koiou E, Dinas K, Tziomalos K, Toulis K, Kandaraki EA, Kalaitzakis E, Katsikis I, Panidis D. The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria. Obesity Facts 2011; 4: 145-150.
70.
Kohan L, Zarei A, Fallahi S, Tabiee O. Association between vaspin rs2236242 gene polymorphism and polycystic ovary syndrome risk. Gene 2014; 539: 209-212.
71.
Aust G, Richter O, Rohm S, Kerner C, Hauss J, Klöting N, Ruschke K, Kovacs P, Youn BS, Blüher M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009; 204: 262-266.
72.
Kadoglou NPE, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S. Serum levels of vaspin and visfatin in patients with coronary artery disease – Kozani study. Clin Chim Acta 2011; 412: 48-52.
73.
Hao F, Zhang H, Zhu J, Kuang H, Yu Q, Bai M, Mu J. Association between vaspin level and coronary artery disease in patients with type 2 diabetes. Diabetes Res Clin Pract 2016; 113: 26-32.
74.
Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, Park JY. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 2011; 413: 264-269.
75.
Sun N, Wang H, Wang L. Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway. Int J Clin Exp Pathol 2015; 8: 482-489.
76.
Esteghamati A, Noshad S, Mousavizadeh M, Zandieh A, Nakhjavani M. Association of vaspin with metabolic syndrome: the pivotal role of insulin resistance. Diabetes Metab J 2014; 38: 143-149.
77.
Karbek B, Bozkurt NC, Topaloglu O, Aslan MS, Gungunes A, Cakal E, Delibasi T. Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome. Minerva Endocrinol 2014; 39: 99-105.
78.
Alnory A, Gad H, Hegazy G, Shaker O. The association of vaspin rs2236242 and leptin rs7799039 polymorphism with metabolic syndrome in Egyptian women. Turk J Med Sci 2016; 46: 1335-1340.
79.
Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metab Clin Exp 2011; 60: 544-549.
80.
Mirzaei K, Hossein-nezhad A, Keshavarz S, Koohdani F, Saboor-Yaraghi AA, Hosseini S, Eshraghian MR, Djalali M. Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects. Diabetol Metab Syndr 2013; 5: 79.
81.
Lu H, Wamba PCF, Lapointe M, Poirier P, Martin J, Bastien M, Cianflone K. Increased vaspin levels are associated with beneficial metabolic outcome pre- and post-bariatric surgery. PLoS One 2014; 9: e111002.
82.
Amouzad Mahdirejei H, Fadaei Reyhan Abadei S, Abbaspour Seidi A, Eshaghei Gorji N, Rahmani Kafshgari H, Ebrahim Pour M, Bagheri Khalili H, Hajeizad F, Khayeri M. Effects of an eight-week resistance training on plasma vaspin concentrations, metabolic parameters levels and physical fitness in patients with type 2 diabetes. Cell J 2014; 16: 367-374.
83.
Hashemi M, Rezaei H, Eskandari-Nasab E, Kaykhaei MA, Zakeri Z, Taheri M. Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report. Gene 2012; 510: 113-117.
84.
Mehanna ET, Mesbah NM, Ghattas MH, Saleh SM, Abo-Elmatty DM. Association of chemerin Rs17173608 and vaspin Rs2236242 gene polymorphisms with metabolic syndrome in Egyptian women. Endocr Res 2016; 41: 43-48.
85.
Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 2011; 22: 331-338.
86.
Mattern A, Zellmann T, Beck-Sickinger AG. Processing, signaling, and physiological function of chemerin. IUBMB Life 2014; 66: 19-26.
87.
De Henau O, Degroot G, Imbault V, Robert V, De Poorter C, Mcheik S, Galés C, Parmentier M, Springael JY. Signaling properties of chemerin receptors CMKLR1, GPR1 and CCRL2. PLoS One 2016; 11: e0164179.
88.
Banas M, Zabieglo K, Kasetty G, Kapinska-Mrowiecka M, Borowczyk J, Drukala J, Murzyn K, Zabel BA, Butcher EC, Schroeder JM, Schmidtchen A, Cichy J. Chemerin is an antimicrobial agent in human epidermis. PLoS One 2013; 8: e58709.
89.
Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population – a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Republic 2008; 152: 217-221.
90.
Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687-4694.
91.
Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, Mahaney MC, Rainwater DL, VandeBerg JL, MacCluer JW, Collier G, Blangero J, Walder K, Jowett JB. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocr Metab 2009; 94: 3085-3088.
92.
Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009; 161: 339-344.
93.
Takahashi M, Inomata S, Okimura Y, Iguchi G, Fukuoka H, Miyake K, Koga D, Akamatsu S, Kasuga M, Takahashi Y. Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism. Endocr J 2013; 60: 37-44.
94.
Landgraf K, Friebe D, Ullrich T, Kratzsch J, Dittrich K, Herberth G, Adams V, Kiess W, Erbs S, Körner A. Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocr Metab 2012; 97: E556-E564.
95.
Menzel J, Biemann R, Aleksandrova K, Schulze MB, Boeing H, Isermann B, Weikert C. The cross-sectional association between chemerin and bone health in peri/pre and postmenopausal women: results from the EPIC-Potsdam study. Menopause 2018; 25: 574-578.
96.
Pfau D, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2010; 33: 171-173.
97.
Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLoS One 2014; 9: e113915.
98.
Cheon DY, Kang JG, Lee SJ, Ihm SH, Lee EJ, Choi MG, Yoo HJ, Kim CS. Serum chemerin levels area associated with visceral adiposity, independent of waist circumference, in newly diagnosed type 2 diabetic subjects. Yonsei Med J 2017; 58: 319.
99.
Andersson DP, Laurencikiene J, Acosta JR, Rydén M, Arner P. Circulating and adipose levels of adipokines associated with insulin sensitivity in nonobese subjects with type 2 diabetes. J Clin Endocrinol Metab 2016; 101: 3765-3771.
100.
Cătoi AF, Suciu Ş, Pârvu AE, Copăescu C, Galea RF, Buzoianu AD, Vereşiu IA, Cătoi C, Pop ID. Increased chemerin and decreased omentin-1 levels in morbidly obese patients are correlated with insulin resistance, oxidative stress and chronic inflammation. Clujul Med 2014; 87: 19-26.
101.
Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N, Morrison S, Carless M, Dyer TD, Cole SA, Goring HH, Moses EK, Walder K, Cawthorne MA, Blangero J, Jowett JB. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metabol 2010; 95: 2476-2485.
102.
Wang D, Yuan GY, Wang XZ, Jia J, Di LL, Yang L, Chen X, Qian FF, Chen JJ. Plasma chemerin level in metabolic syndrome. Genet Mol Res 2013; 12: 5986-5991.
103.
Sell H, Divoux A, Poitou C, Basdevant A, Bouillot J, Bedossa P, Tordjman J, Eckel J, Clément K. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metabol 2010; 95: 2892-2896.
104.
Ress C, Tschoner A, Engl J, Klaus A, Tilg H, Ebenbichler CF, Patsch JR, Kaser S. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Investig 2010; 40: 277-280.
105.
Kim SH, Lee SH, Ahn KY, Lee DH, Suh YJ, Cho SG, Choi YJ, Lee DH, Lee SY, Hong SB, Kim YS, Jeon JY, Nam M. Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes. Clin Endocrinol 2014; 80: 825-833.
106.
Stefanov T, Blüher M, Vekova A, Bonova I, Tzvetkov S, Kurktschiev D, Temelkova-Kurktschiev T. Circulating chemerin decreases in response to a combined strength and endurance training. Endocrine 2014; 45: 382-391.
107.
Liu M, Lin X, Wang X. Decrease in serum chemerin through aerobic exercise plus dieting and its association with mitigation of cardio-metabolic risk in obese female adolescents. J Pediatr Endocrinol Metabol 2018; 31: 127-135.
108.
Tönjes A, Fasshauer M, Kratzsch J, Stumvoll M, Blüher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 2010; 5: e13911.
109.
Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, Boden G, Li L. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med 2010; 58: 883-886.
110.
Fatima SS, Bozaoglu K, Rehman R, Alam F, Memon AS. Elevated chemerin levels in Pakistani men: an interrelation with metabolic syndrome phenotypes. PLoS One 2013; 8: e57113.
111.
Habib SS, Eshki A, AlTassan B, Fatani D, Helmi H, AlSaif S. Relationship of serum novel adipokine chemerin levels with body composition, insulin resistance, dyslipidemia and diabesity in Saudi women. Eur Rev Med Pharmacol Sci 2017; 21: 1296-1302.
112.
Roman AA, Parlee SD, Sinal CJ. Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine 2012; 42: 243-251.
113.
El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diab Med 2011; 28: 1194-1200.
114.
Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol 2010; 72: 342-348.
115.
Gateva A, Assyov Y, Tsakova A, Kamenov Z. Classical (adiponectin, leptin, resistin) and new (chemerin, vaspin, omentin) adipocytokines in patients with prediabetes. Horm Mol Biol Clin Investig 2018. doi:10.1515/hmbci-2017-0031.
116.
Gorkem U, Kucukler FK, Togrul C, Gungor T. Are adipokines associated with gestational diabetes mellitus? J Turk Germ Gynecol Assoc 2016; 17: 186-190.
117.
Fatima SS, Alam F, Chaudhry B, Khan TA. Elevated levels of chemerin, leptin, and interleukin-18 in gestational diabetes mellitus. J Matern Fetal Neonatal Med 2017; 30: 1023-1028.
118.
Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med 2011; 50: 1093-1097.
119.
Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine 2012; 41: 281-288.
120.
Motawi TMK, Mahdy SG, El-Sawalhi MM, Ali EN, El-Telbany RFA. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis. Can J Physiol Pharmacol 2018; 96: 38-44.
121.
Xiaotao L, Xiaoxia Z, Yue X, Liye W. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis 2012; 23: 412-416.
122.
Hah Y, Kim NK, Kim MK, Kim HS, Hur S, Yoon H, Kim YN, Park KG. Relationship between chemerin levels and cardiometabolic parameters and degree of coronary stenosis in Korean patients with coronary artery disease. Diabetes Metab J 2011; 35: 248-254.
123.
Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol 2010; 185: 3728-3739.
124.
Menzel J, di Giuseppe R, Biemann R, Wittenbecher C, Aleksandrova K, Eichelmann F, Fritsche A, Schulze MB, Boeing H, Isermann B, Weikert C. Association between chemerin, omentin-1 and risk of heart failure in the population-based EPIC-Potsdam study. Sci Rep 2017; 7: 14171.
125.
Aydin K, Canpolat U, Akin S, Dural M, Karakaya J, Aytemir K, Özer N, Gürlek A. Chemerin is not associated with subclinical atherosclerosis markers in prediabetes and diabetes. Anatol J Cardiol 2015; 16: 749-755.
126.
Ebert T, Gebhardt C, Scholz M, Wohland T, Schleinitz D, Fasshauer M, Blüher M, Stumvoll M, Kovacs P, Tönjes A. Relationship between 12 adipocytokines and distinct components of the metabolic syndrome. J Clin Endocrinol Metabol 2018; 103: 1015-1023.
127.
Aronis KN, Sahin-efe A, Chamberland JP, Iii AS, Vokonas P, Mantzoros CS. Chemerin levels as predictor of acute coronary events: a case–control study nested within the veterans affairs normative aging study. Metabolism 2014; 63: 760-766.
128.
Zhuang X, Sun F, Li L, Jiang D, Li X, Sun A, Pan Z, Lou N, Zhang L, Lou F. Therapeutic effect of metformin on chemerin in non-obese patients with non-alcoholic fatty liver disease (NAFLD). Clin Labor 2015; 61: 1409-1414.
129.
Mohamed AA. Circulating adipokines in children with nonalcoholic fatty liver disease: possible noninvasive diagnostic markers. Ann Gastroenterol 2017; 30: 457-463.
130.
Zwolak A, Szuster-Ciesielska A, Daniluk J, Semeniuk J, Kandefer-Szerszen M. Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease. Ann Hepatol 2016; 15: 862-869.
131.
Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metab Clin Exp 2016; 65: 1062-1079.
132.
Yang S, Wang Q, Huang W, Song Y, Feng G, Zhou L, Tan J.Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women? Gynecol Endocr 2016; 32: 38-41.
133.
Movahed Z, Kohan L, Fallahi S, Tabiee O. Influence of chemerin rs17173608 polymorphism on polycystic ovary syndrome susceptibility. Taiwan J Obstet Gynecol 2015; 54: 280-283.
134.
Adrych K, Stojek M, Smoczynski M, Sledzinski T, Sylwia S, Swierczynski J. Increased serum chemerin concentration in patients with chronic pancreatitis. Dig Liver Dis 2012; 44: 393-397.
135.
Shin H, Lee DC, Chu SH, Jeon JY, Lee MK, Im JA, Lee JW. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin Endocrinol 2012; 77: 47-50.
136.
Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes 2013; 2013: 393192.
137.
Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocr Metabol 2013; 98: E514-E517.
138.
Chu SH, Lee MK, Ahn KY, Im J, Park MS, Lee DC, Jeon JY, Lee JW. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 2012; 7: e34710.
139.
Aksan G, İnci S, Nar G, Soylu K, Gedikli Ö, Yüksel S, Özdemir M, Nar R, Meriç M, Şahin M. Association of serum chemerin levels with the severity of coronary artery disease in patients with metabolic syndrome. Int J Clin Exp Med 2014; 7: 5461-5468.
140.
Eriksson JG, Venojärvi M, Osmond C. Prenatal and childhood growth, chemerin concentrations, and metabolic health in adult life. Int J Endocrinol 2016; 2016: 3838646.
141.
Tönjes A, Scholz M, Breitfeld J, Marzi C, Grallert H, Gross A, Ladenvall C, Schleinitz D, Krause K, Kirsten H, Laurila E, Kriebel J, Thorand B, Rathmann W, Groop L, Prokopenko I, Isomaa B, Beutner F, Kratzsch J, Thiery J, Fasshauer M, Klöting N, Gieger C, Blüher M, Stumvoll M, Kovacs P. Genome wide meta-analysis highlights the role of genetic variation in RARRES2 in the regulation of circulating srum chemerin. PLoS Genet 2014; 10: e1004854.
142.
Min JL, Nicholson G, Halgrimsdottir I, Almstrup K, Petri A, Barrett A, Travers M, Rayner NW, Mägi R, Pettersson FH, Broxholme J, Neville MJ, Wills QF, Cheeseman J; GIANT Consortium; MolPAGE Consortium, Allen M, Holmes CC, Spector TD, Fleckner J, McCarthy MI, Karpe F, Lindgren CM, Zondervan KT. Coexpression network analysis in abdominal and gluteal adipose tissue reveals regulatory genetic loci for metabolic syndrome and related phenotypes. PLoS Genet 2012; 8: e1002505.
143.
Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, Ogura Y, Yuasa D, Matsuo K, Nagata T, Oba T, Yasukawa H, Numaguchi Y, Sone T, Murohara T, Ouchi N. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J Am Coll Cardiol 2014; 63: 2722-2733.
144.
Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, Kataoka Y, Ohashi K, Daida H, Kihara S, Ogawa H, Murohara T, Ouchi N. Fat-derived factor omentin stimulates edothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012; 287: 408-417.
145.
Brunetti L, Leone S, Orlando G, Ferrante C, Recinella L, Chiavaroli A, Di Nisio C, Shohreh R, Manippa F, Ricciu-ti A, Vacca M. Hypotensive effects of omentin-1 related to increased adiponectin and decreased interleukin-6 in intra-thoracic pericardial adipose tissue. Pharmacol Rep 2014; 66: 991-995.
146.
Watanabe K, Watanabe R, Konii H, Shirai R, Sato K, Matsuyama T, Ishibashi-UedaH, Koba S, Kobayashi Y, Hirano T, Watanabe T. Counteractive effects of omentin-1 against atherogenesis. Cardiovasc Res 2016; 110: 118-128.
147.
Duan XY, Xie PL, Ma YL, Tang SY. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 2011; 41: 1223-1231.
148.
Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF--induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012; 686: 116-123.
149.
de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
150.
Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 257-263.
151.
Moreno-Navarrete J, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G, Fernández-Real JM. Circulating omentin concentration increases after weight loss. Nutr Metab 2010; 7: 27.
152.
Lesná J, Tichá A, Hyšpler R, Musil F, Bláha V, Sobotka L, Zadák Z, Šmahelová A. Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutr Diabetes 2015; 5: e183-e183.
153.
Vu A, Sidhom MS, Bredbeck BC, Kosmiski LA, Aquilan-te CL. Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetol Metab Syndr 2014; 6: 4.
154.
Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Ha-re P, Lehnert H, Randeva HS. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-808.
155.
Luque-Ramirez M, Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Alpanes M, Escobar-Morreale HF. Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Hum Reprod 2013; 28: 1908-1918.
156.
Zhou JY, Chan L, Zhou S. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 2014; 12: 136-143.
157.
Sitticharoon C, Nway NC, Chatree S, Churintaraphan M, Boonpuan P, Maikaew P. Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors. Peptides 2014; 62: 164-175.
158.
Wang C. Obesity, inflammation, and lung injury (OILI): the good. Mediators Inflamm 2014; 2014: 978463.
159.
Zabetian-Targhi F, Mirzaei K, Keshavarz SA, Hossein-Nezhad A. Modulatory role of omentin-1 in inflammation: cytokines and dietary intake. J Am Coll Nutr 2016; 35: 670-678.
160.
Barker G, Lim R, Georgiou HM, Lappas M. Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. PLoS One 2012; 7: e42943.
161.
Montazerifar F, Bakhshipour A, Karajibani M, Torki Z, Dashipour A. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci 2017; 22: 70.
162.
Catli G, Anik A, Abaci A, Kume T, Bober E. Low omentin-1 levels are related with clinical and metabolic parameters in obese children. Exp Clin Endocr Diabetes 2013; 121: 595-600.
163.
Oświęcimska J, Suwała A, Świętochowska E, Ostrowska Z, Gorczyca P, Ziora-Jakutowicz K, Machura E, Szczepańska M, Kukla M, Stojewska M, Ziora D, Ziora K. Serum omentin levels in adolescent girls with anorexia nervosa and obesity. Physiol Res 2015; 64: 701-709.
164.
Zhang M, Tan X, Yin C, Wang L, Tie Y, Xiao Y. Serum levels of omentin-1 are increased after weight loss and are particularly associated with increases in obese children with metabolic syndrome. Acta Paediatr 2017; 106: 1851-1856.
165.
Hamnvik OP, Thakkar B, Chamberland J, Aronis K, Schneider B, Mantzoros CS. Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day–night variation. Int J Obes 2015; 39: 260-264.
166.
Nway NC, Sitticharoon C, Chatree S, Maikaew P. Correlations between the expression of the insulin sensitizing hormones, adiponectin, visfatin, and omentin, and the appetite regulatory hormone, neuropeptide Y and its receptors in subcutaneous and visceral adipose tissues. Obes Res Clin Pract 2016; 10: 256-263.
167.
Splichal Z, Bienertova-Vasku J, Novak J, Zlamal F, Tomandl J, Tomandlova M, Forejt M, Havlenova S, Jackowska A, Vasku A. The common polymorphism Val109Asp in the omentin gene is associated with daily energy intake in the Central-European population. Nutr Neurosci 2015; 18: 41-48.
168.
Isakova ZT, Talaibekova ET, Asambaeva DA, Kerimkulova AS, Lunegova OS, Aldasheva NM, Aldashev AA. A polymorphic marker Val109Asp in the omentin gene are associated with abdominal obesity in the Kyrgyz population. Probl Endocrinol 2016; 62: 4-8.
169.
Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010; 28: 993-998.
170.
Ouerghi N, Ben Fradj MK, Bezrati I, Feki M, Kaabachi N, Bouassida A. Effect of high-intensity interval training on plasma omentin-1 concentration in overweight/obese and normal-weight youth. Obes Facts 2017; 10: 323-331.
171.
Wilms B, Ernst B, Gerig R, Schultes B. Plasma omentin-1 levels are related to exercise performance in obese women and increase upon aerobic endurance training. Exp Clin Endocrinol Diab 2015; 123: 187-192.
172.
Zehsaz F, Farhangi N, Ghahramani M. The response of circulating omentin-1 concentration to 16-week exercise training in male children with obesity. Phys Sportsmed 2016; 44: 355-361.
173.
Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diab Res Clin Pract 2010; 88: 29-33.
174.
Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005; 1732: 96-102.
175.
Akour A, Kasabri V, Boulatova N, Bustanji Y, Naffa R, Hyasat D, Khawaja N, Bustanji H, Zayed A, Momani M. Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. Acta Diabetol 2017; 54: 163-170.
176.
Arman Y, Kirna K, Ugurlukisi B, Kutlu O, Dikker O, Cil E, Akarsu M, Ozcan M, Yuruyen G, Demir P, Altun O, Ozsenel EB, Erdem MG, Sandikci R, Tukek T. The effects of blood glucose regulation in omentin-1 levels among diabetic patients. Exp Clin Endocrinol Diabetes 2017; 125: 262-266.
177.
Wan W, Li Q, Zhang F, Zheng G, Lv Y, Wan G, Jin X. Serum and vitreous concentrations of omentin-1 in diabetic retinopathy. Dis Markers 2015; 2015: 754312.
178.
Tang Y, Yu J, Zeng Z, Liu Y, Liu J, Xu J. Circulating omentin-1 levels in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol 2017; 33: 244-249.
179.
Zirlik S, Hildner KM, Targosz A, Neurath MF, Fuchs FS, Brzozowski T, Konturek PC. Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome? J Physiol Pharmacol 2013; 64: 353-360.
180.
Wang Q, Feng X, Zhou C, Li P, Kang J. Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome. Ann Clin Biochem 2013; 50: 230-235.
181.
Senolt L, Polanska M, Filkova M, Cerezo LA, Pavelka K, Gay S, Haluzik M, Vencovsky J. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1410-1411.
182.
Wittenbecher C, Menzel J, Carstensen-Kirberg M, Biemann R, di Giuseppe R, Fritsche A, et al. Omentin-1, adiponectin, and the risk of developing type 2 diabetes. Diabetes Care 2016; 39: e79-e80.
183.
Herder C, Kannenberg JM, Niersmann C, Huth C, Carstensen-Kirberg M, Wittenbecher C, Schulze MB, Blüher M, Rathmann W, Peters A, Roden M, Meisinger C, Thorand B. Independent and opposite associations of serum levels of omentin-1 and adiponectin with increases of glycaemia and incident type 2 diabetes in an older population: KORA F4/FF4 study. Eur J Endocrinol 2017; 177: 277-286.
184.
Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46: 91-97.
185.
Harada K, Shibata R, Ouchi N, Tokuda Y, Funakubo H, Suzuki M, Kataoka T, Nagao T, Okumura S, Shinoda N, Kato B, Sakai S4, Kato M, Marui N, Ishii H, Amano T, Matsubara T, Murohara T.. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis 2016; 251: 299-304.
186.
Yoruk U, Yaykasli KO, Ozhan H, Memisogullari R, Karabacak A, Bulur S, Aslantaş Y, Başar C, Kaya E. Association of omentin Val109Asp polymorphism with coronary artery disease. Anatol J Cardiol 2014; 14: 511-514.
187.
Jamshidi J, Ghanbari M, Asnaashari A, Jafari N, Valizadeh GA. Omentin Val109Asp polymorphism and risk of coronary artery disease. Asian Cardiovasc Thorac Ann 2017; 25: 199-203.
188.
Nazar S, Zehra S, Azhar A. Association of single nucleotide missence polymorphism Val109Aspof omentin-1 gene and coronary artery disease in Pakistani population: multicenter study. Pakistan J Med Sci 2017; 33: 1128-1135.
189.
Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012; 4: 37.
190.
Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diab Res Clin Pract 2011; 93: 21-25.
191.
Alizadeh S, Mirzaei K, Mohammadi C, Keshavarz SA, Maghbooli Z. Circulating omentin-1 might be associated with metabolic health status in different phenotypes of body size. Arch Endocrinol Metab 2017; 61: 567-574.
192.
Kilic DC, Oguz A, Uzunlulu M, Celik S, Koroglu G. Plasma omentin-1 levels are similar in nondiabetic metabolic syndrome patients and healthy subjects. J Endocrinol Metab 2011; 1: 182-187.
193.
Prats-Puig A, Bassols J, Bargalló E, Mas-Parareda M, Ribot R, Soriano-Rodríguez P, Berengüí À, Díaz M, de Zegher F, Ibánez L, López-Bermejo A. Toward an early marker of metabolic dysfunction: Omentin-1 in prepubertal children. Obesity 2011; 19: 1905-1907.
194.
Buyukinan M, Atar M, Can U, Pirgon O, Guzelant A, Deniz I. The association between serum vaspin and omentin-1 levels in obese children with metabolic syndrome. Metab Syndr Rel Disord 2018; 16: 76-81.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
